Portal de Periódicos da CAPES

Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients

2012; Elsevier BV; Volume: 24; Issue: 3 Linguagem: Inglês

10.1093/annonc/mds534

1569-8041

Marius Ilié, Elodie Long‐Mira, Véronique Hofman, Bérengère Dadone, Charles‐Hugo Marquette, Jérôme Mouroux, Jean-Michel Vignaud, Hugues Bégueret, Jean‐Philippe Merlio, David Capper, Andreas von Deimling, J.-F. Emile, Paul Hofman,

Cancer Mechanisms and Therapy

ABSTRACT Background Non-small-cell lung carcinoma (NSCLC) patients with a BRAF V600E mutation benefit from targeted therapy. The usefulness of immunohistochemistry (IHC) as an alternative approach for the detection of BRAF V600E in NSCLC patients has not been evaluated until now. This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF V600E in primary lung adenocarcinoma. Patients and methods BRAF mutations were analysed by DNA sequencing of a Caucasian subpopulation of selected 450 of 1509 (30%) EGFR , KRAS , PI3KA, Her2 and EML4-ALK wild-type (wt) primary lung adenocarcinomas. Detection of the BRAF V600E mutation was carried out by IHC using the VE1 clone antibody and compared with the results of other molecular methodologies. Results Of 450 (9%) of tumours, 40 harboured a BRAF mutation, which corresponded to either a BRAF V600E or a non- BRAF V600E mutation in 21 of 450 (5%) and 19 of 450 (4%) cases, respectively. The IHC VE1 assay was positive in 19 of 21 (90%) BRAF V600E -mutated tumours and negative in all BRAF nonV600E -mutated tumours. Conclusion IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF V600E and may be an alternative to molecular biology for the detection of mutations in NSCLC.